Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.

British journal of cancer - 11 Apr 2017

Kinsler Veronica A, O'Hare Patricia, Jacques Thomas, Hargrave Darren, Slater Olga

Abstract excerpt

BACKGROUND: Primary melanoma of the CNS in children is extremely rare, and usually linked to congenital melanocytic naevus syndrome, caused by mosaicism for oncogenic NRAS mutations. Outcome is fatal in all cases. Data from murine and in vitro studies suggest that MEK inhibition is a possible therapeutic option. METHODS: Four children with NRAS-mutated CNS melanoma were treated with Trametinib on a compassionate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Central Nervous System Neoplasms
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Pyridones

Share to Pyrimidinones

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28253523
DOI: 10.1038/bjc.2017.49
PMCID: PMC5396107

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.PMID 28253523Read ↗

Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects.Semantic proximity Read ↗

Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in MelanocytesSemantic proximity Read ↗

Melanoma in congenital melanocytic naevi.Semantic proximity Read ↗

The role of MEK inhibitors in the treatment of metastatic melanoma.Semantic proximity Read ↗

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.Semantic proximity Read ↗

Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling.Semantic proximity Read ↗

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor.Semantic proximity Read ↗

Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.Semantic proximity Read ↗

Neurocutaneous Melanocytosis and Leptomeningeal Melanoma.Semantic proximity Read ↗

NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.Semantic proximity Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

Mosaic BRAF Fusions Are a Recurrent Cause of Congenital Melanocytic Nevi Targetable by MAPK Pathway Inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.